← Zealand Pharma A/S (ZEAL) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Zealand Pharma A/S (ZEAL)
Healthcare · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-31 (est.)
Phase 3
Pipeline
20
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-10-31 (est.)Phase 3 · Glepaglutideimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| GlucaGen | Phase 3 | Hypoglycemia |
| Petrelintide | Phase 2 | Obesity |
| danegaptide | Phase 2 | Focus of Study is STEMI |
| Glepaglutide | Phase 3 | Short Bowel Syndrome |
| dasiglucagon | Phase 3 | Hypoglycemia |
| ZP4207(dasiglucagon) glucagon analogue | Phase 2 | Diabetes Mellitus Type 1 |
| ZP1848 | Phase 2 | Short Bowel Syndrome |
| Insulin Lispro | Phase 2 | Diabetes Mellitus, Type 1 |
| ZP4207 | Phase 2 | Hypoglycemia |
| Anakinra (Kineret®) | Phase 2 | Premature Infants |
| Melatonin (N-acetyl-5-methoxytryptamine) | Phase 3 | Depression |
| Methoxyflurane | Phase 3 | Cancer |
| Anakinra | Phase 2 | Prematurity; Extreme |
| Denosumab | Phase 2 | Gout |
| Omalizumab Injection | Phase 2 | Asthma |
| Epoetin Alfa | Phase 3 | Traumatic Brain Injury |
| Fibrinogen Concentrate | Phase 3 | Trauma |
| Incobotulinumtoxin-A | Phase 2 | Diabetic Neuropathy, Painful |
| acetylsalicyclic acid (ASA) | Phase 3 | Covert Brain Infarction |
| Dexamethasone Oral | Phase 3 | Rheumatic Fever |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ZEAL (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.